BALCAO · PHARMACEUTICAL PREPARATIONS
Kaya Holdings, Inc. KAYS
17 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$7,134
▼ 96.4% vs FY2023
EPS · FY24
$-0.07
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-29168.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 7,134.00
Revenue, FY2024 · full 17-year series below
Revenue
Net income
The company lost 29168 cents on every revenue dollar this year.
Per share
USD -0.07
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-28343.5%
Net margin-29168.2%
Return on assets-962.9%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−62.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−80.0%
−62.9%
−20.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2024
Change, 5 years+142.2%
Change, 10 years—
The share count grew 142% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 216,369.00
total assets, end of FY2024
Total assetsUSD 216,369.00
EquityUSD -15.0M
CashUSD 39,668.00
Current ratio0.01×
Equity funds -6946% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
EBITDA $B
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
·
Income tax $B
·
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.07
0.01
·
·
−0.92
0.02
0.01
−0.12
−0.20
−0.04
−0.03
−0.01
0.01
−0.07
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Shares out B
0.04
0.02
0.02
0.01
0.01
0.01
0.17
0.14
0.12
0.09
0.08
0.07
0.07
0.06
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
50 of 51
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 1 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed